Barrier mechanisms in the brain are important for its normal functioning and development.
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F1000Research prevent the entry of many drugs of therapeutic potential into the brain. We outline those that have been tried and discuss why they may so far have been largely unsuccessful. Currently, a promising approach appears to be focal, reversible disruption of the blood-brain barrier using focused ultrasound, but more work is required to evaluate the method before it can be tried in patients. Overall, our view is that much more fundamental knowledge of barrier mechanisms and development of new experimental methods will be required before drug targeting to the brain is likely to be a successful endeavor. In addition, such studies, if applied to brain pathologies such as stroke, trauma, or multiple sclerosis, will aid in defining the contribution of brain barrier pathology to these conditions, either causative or secondary.
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Introduction
The term blood-brain barrier has a long history. Its current usage describes the structural, physiological, and molecular mechanisms that control the exchange (entry and exit) of molecules between the blood and the brain. The sum of these mechanisms results in the characteristically stable internal environment of the brain, both during development and in the adult. This has been an often confused and misunderstood field of neuroscience.
The main aim of this review is to explain what is known about brain barrier mechanisms and why understanding these mechanisms is fundamental to understanding normal brain development and normal brain function and how disorders of brain barrier mechanisms may contribute to a range of neuropathological conditions. We suggest that the neuroscience community should pay more attention to this topic and we advocate the need for new researchers to move into this intriguing and important field, as major advances in many fields have often come from an influx of new people unfettered by the prevailing dogmas.
The other focus of this review will be to consider the clinically important problem of developing ways to deliver drugs to the brain for treating neurological and psychiatric disorders. This has been a major effort in the blood-brain barrier field for the past 20-30 years but has yielded little of practical value. We list the diverse attempts that have been tried, we analyze some of the possible reasons why they have been unsuccessful, and we suggest some alternative/new approaches to the problem.
What is meant by the term "blood-brain barrier"?
The use of the term "barrier" is in many ways unfortunate 1 , as for those outside the field it disguises the multiplicity of mechanisms involved. Perhaps this also explains the almost exclusive focus of people interested in pathological conditions involving the bloodbrain barrier on tests of its integrity, largely ignoring until recently the numerous cellular mechanisms at the various blood-brain interfaces that may be disrupted. Almost all of the early work on the blood-brain barrier involved the use of dyes, which could be visualized. This field has recently been reviewed with translations from key oft-cited papers published in their original languages showing that many of the citations were incorrect 2 . To set the record straight, it was Lena Stern who was the first to coin the term blood-brain barrier ("barrière hémato-encéphalique" 3 ) and not, as often cited, Ehrlich 4 , Lewandowsky 5 , or Goldmann 6 . The current understanding of the term "blood-brain barrier" is that it covers a number of morphological entities and a plethora of cellular transport mechanisms both inward and outward, which we next describe briefly.
Morphology of blood-brain barrier interfaces
There are six interfaces to be considered. Figure 1 illustrates their sites and main morphological features. An essential component of all interfaces with barrier properties is the presence of specialized junctions between the cells of the interface. In most of the barriers, these junctions are tight junctions; they restrict the movement of molecules between the endothelial and the epithelial cells. As a direct consequence of this restriction, the intercellular junctions have the important functional effect of allowing the numerous transporters within individual cells to operate over the large surface of the barrier interfaces; without this permeability restriction, the inward and outward transporter mechanisms would be ineffective. In recent years, it has become increasingly apparent that there is a much greater complexity involved in the structural organization of the brain barriers; in the case of the blood-brain barrier itself, this includes astrocytes, pericytes, basement membrane, and extracellular matrix (Figure 1) . However, there is much to be learned about the precise role of individual morphological components of the brain barriers and their interactions in normal and pathological brains [7] [8] [9] [10] . We shall now consider each barrier interface in turn: (a) the meningeal barrier, shown in Figure 1(a) , is structurally the most complex of all the brain barriers and is situated at the meninges (pia, arachnoid, and dura mater). The barrier-forming cells are the outer layer of the arachnoid membrane (the arachnoid barrier cells), which have tight junctions between adjacent cells forming a physical barrier between the outer cerebrospinal fluid (CSF) in the subarachnoid space and more superficial dural layers (dural border cells and the dura mater). The blood vessels in the subarachnoid space have tight junctions with similar barrier characteristics as cerebral blood vessels, although lacking the surrounding pericytes and astrocytic end-feet [11] [12] [13] . In contrast, blood vessels within the dura mater are fenestrated; other important components of the barrier are the basement membrane and glia limitans. Figure 1(d) . These include the median eminence, pineal gland, area postrema, and subfornical organ. The blood vessels have permeability characteristics similar to elsewhere in the body and have the functional property of allowing feedback penetration of peptide hormones controlled by the hypothalamic-pituitary axis. These peptides and other molecules are prevented from entering the CSF by tanycytes, the specialized ependymal cells of these brain areas, connected by tight junctions between their apices; entry into the rest of the brain is prevented by tight junctions between astroglial cells 19, 20 . (e) Ependyma in adult brain, shown in Figure 1 (e). Apart from areas where there are specialized tanycytes, ependymal cells are linked by gap junctions that do not restrict exchange of even large molecules, such as proteins, between CSF and interstitial space of brain 11, 21 . (f) The embryonic CSF-brain barrier, shown in Figure 1 (f). In the ventricular zone is a temporary barrier between the CSF and brain parenchyma 21 . In early brain development, strap junctions are present between adjacent neuroepithelial cells; these form a physical barrier restricting the movement of larger molecules, such as proteins, but not smaller molecules 22, 23 . At later stages of development and in the adult brain, these strap junctions are no longer present when this interface becomes ependyma.
Transport mechanisms at barrier interfaces
Control of the interstitial ionic environment of the brain This is absolutely critical for normal function of the brain. As Hugh Davson once put it (paraphrased), without this control our sensory experience would be limited to a series of flashes and bangs. The ionic composition of the interstitial fluid is usually taken to be synonymous with the composition of CSF 24 . This, plus the obvious practical point that it is relatively easy to sample CSF, has led to a focus on CSF and the choroid plexus in both the adult 25 and the developing 26 brain; however, CSF composition generally does not reflect blood-brain barrier function (see Text Box). There is a good correlation between expression levels of transporters and ionic concentrations at different ages, at least in the rat (Figure 2 and Figure 3 ).
Influx mechanisms
These have been extensively studied only at the blood-brain barrier itself and at the blood-CSF barrier (choroid plexuses). A limitation of early studies with radiolabeled molecules, such as glucose and amino acids, was that it was difficult to distinguish between brain entry and incorporation of labeled molecules into metabolic pathways. This problem was solved by Oldendorf 27 with his short pass technique. In general, essential amino acids were transported into the brain to a greater extent than non-essential amino acids; there was also a high uptake of D-glucose 27 . The molecular basis for these inward transport mechanisms has been extensively investigated using gene expression techniques to study the blood-brain barrier itself [28] [29] [30] and also the choroid plexuses 26, [31] [32] [33] . These studies have revealed a plethora of genes, particularly those classed as solute linked carriers (SLCs) 34 . These are summarized in Figure 4 for transporters identified in both the transcriptome and the proteome in human endothelial cells 29 . Some of these carriers will transport only compounds that closely resemble endogenous substrates, as they exhibit high substrate specificity (e.g. GLUT1). Many others (e.g. organic anion transporters [OATs] , OAT polypeptides [OATPs] , and large amino acid transporter [LAT1]) will accept a broader range of substrates; they provide a potential route of entry into the central nervous system (CNS) for exogenous compounds. Members of the OAT family of solute carriers (SLC) are known to transport a wide range of drugs, such as aspirin, ibuprofen, and various antibiotics, and pesticides (e.g.
and the drug L-DOPA both have amino acid structures that allow entry via the amino acid transporter LAT1. Some environmental toxins are also able to gain entry into the CNS by attaching themselves to an endogenous substrate to be co-transported; for example, methyl-mercury (MeHg) and lead (Pb 2+ ) attached to cysteine enter via amino acid transporters specific for this amino acid, e.g. SLC1A5 and SLC7A10.
Many more Slc genes have been identified in the transcriptome of mouse endothelial cells 28 . A large number was also identified in mouse lateral ventricular choroid plexuses 33 . For comparison between the two interfaces, see 34. It is striking that the expression of some Slc genes in brain barriers is much higher in the developing brain 28, 35 ; this correlates with limited information of greater transport of some labeled amino acids and glucose into the developing brain, suggesting that the high expression levels correlate with transporter function (reviewed in 36). Probably several Slcs are responsible for the transport of the same molecules, indicating a significant degree of redundancy.
Efflux mechanisms
Of particular importance in relation to drug entry into the brain, or rather the failure of most drugs to enter the brain, are the ABC efflux transporters 37, 38 . There are 49 members of the ABC protein superfamily (http://nutrigene.4t.com/humanabc.htm). Many of these are efflux transporters. At the blood-brain barrier interface (Figure 5 ), the efflux transporters that have been shown to be expressed and present and appear to be of particular functional importance are ABCB1 (also known as P-glycoprotein [PGP] , and MRP5 47 are localized to the luminal membrane, where they export compounds into the blood. In choroid plexus epithelial cells (blood-CSF barrier), MRP1, MRP4, and BCRP are localized to the basolateral membranes where they export compounds into the stroma of the plexus 40, 48, 49 . The subcellular localization of PGP in choroid plexus is not clear. Some studies report staining too low to be able to determine localization 40, 48 or positive staining, but localization was not able to be determined 50, 51 . Other studies report cytosolic 52 or subapical localization 42 . One study has reported apical membrane localization in cultured choroid plexus epithelial cells 53 . A common feature of these outwardly directed efflux transporters is a broad substrate specificity and considerable overlap between transporters (see 54). PGP is unusual in that it intercepts lipid-soluble compounds (red symbols, Figure 5 ) as they pass through the internal leaflet of the plasma membrane and returns them to the extracellular fluid 55 , whereas BCRP and the MRPs bind their substrates from within the cell cytoplasm. Compounds can be exported from the cell by one or more of these efflux pathways. For example, a lipid-soluble compound that manages to avoid interception by PGP as it passes into the cell may then be metabolized by phase I enzymes (e.g. cytochrome P450 oxidases), conjugated by phase II enzymes (sulfotransferases [SULTs], uridine-diphospho-glucuronosyltransferase [UGT], or glutathione S-transferase [GST]), and exported by BCRP and/or MRP.
There are probably species differences in the level of expression and function of these various efflux transporters, and it is known that their expression changes with age during brain development at both interfaces 28, 35, 40, 56, 57 . No doubt with further studies other members of this large group of transporters will be found to be functional at one or more of the brain barrier interfaces. ABC transporters that have been identified at different brain barriers are shown in Figure 5 , together with an indication of differences in mechanisms of their function. 
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. CSF secretion results from coordinated transport of ions and water from basolateral membrane to cytoplasm, then sequentially across apical membrane into ventricles 25 . The genes for many of these transporters and ion channels are differentially expressed in the embryo compared to the adult. This is represented in the three panels. It is emphasized that this represents differential expression, not the absence of a gene at one age (details are in 35 . Polarized distribution of carbonic anhydrase (CAR) and Na + /K + -ATPases, and aquaporins, enable net ion and water translocation to CSF (see 100 and 102 for reviews). CLCKA (CLCK1) is an inwardly rectifying chloride channel; its gene (Clcnka) in embryonic choroid plexus is expressed many orders of magnitude higher than in the adult. Clcnkb is expressed at a higher level in the adult. CAR2 has an intracellular distribution and is functionally important for catalyzing the equilibrium that generates H + and HCO 3 -, which is an important part of the mechanism secreting CSF. There are many more channels that show age-related differential expression in choroid plexus, the functions of which are unclear 26 .
Figure 3. Ion gradients between CSF and plasma in developing and adult rat brain.
A characteristic of CSF is its stable ionic composition that differs from that of plasma to an extent that cannot be explained by ultrafiltration, as was once thought 24 . Data for CSF and plasma (m-equiv/L water) are from 103 and for intracellular ions (mmol/L water) from Figure 8 in 104. The gradients are the consequence of the complex interactions between enzymes (notably carbonic anhydrase) ion transporters and ion channels, as illustrated in Figure 2 . The CSF secretion rate in the embryo and newborn is much lower than in the adult [105] [106] [107] , which is perhaps explained by the much lower expression of carbonic anhydrase and ATPases in the developing choroid plexus. . Tight junctions (tj) between adjacent cells prevent the paracellular passage of hydrophilic compounds. R-M = receptormediated, GLUT = glucose transporters, NTs = nucleoside transporters, AAs = amino acid transporters (includes LAT), OATP = organic anion transporting polypeptides, OAT = organic anion transporters, OCT = organic cation transporters, MCT = monocarboxylate transporters, FATP = fatty acid transport protein. Many of these transporters are solute linked carriers (SLCs). Both SLC designations and the original abbreviations are included here. SLC1A2/EAAT2, SLC1A3/EAAT1 high-affinity glutamate, SLC1A4/ASCT1 glutamate/neutral amino acids, SLC2A1/GLUT1, SLC2A3,14/GLUT3 glucose, SLC3A2/4F2hc amino acid transporter heavy chain, SLC6A12/BGT1 neurotransmitter, SLC7A1/CAT1 cationic amino acid, y+ system, SLC7A5/LAT1 amino acid light chain, L system, SLC10A1/NTCP sodium/bile acid cotransporter. SLC16A1/MCT1, SLC16A2/MCT8 monocarboxylates, SLC19A1/RFC folate, SLC22A1/OCT1 organic cations, SLC22A3/OCTN3 organic cations, SLC22A5/OCTN2 organic cation/carnitine, SLC27A1/FATP1 fatty acid, SLC29A1/ENT1 equilibrative nucleosides, SLCO2B1/OATP2B1 organic anions, SLCO1B1/OATP1B1 organic anions. Examples of receptor-mediated transporters are insulin receptor (INSR), transferrin receptor (TFR1), leptin receptor (LEPR), low-density lipoprotein receptor (LDLR), and insulin-like growth factor receptor (IGFR). , and MRP5 47 are localized to the luminal membrane where they export compounds into the blood. In choroid plexus epithelial cells (blood-CSF barrier), MRP1, MRP4, and BCRP are localized to the basolateral membranes where they export compounds into the stroma of the plexus 40, 48, 49 . The subcellular localization of PGP in choroid plexus is not clear. Some studies report staining too low to be able to determine localization 40, 48 or positive staining, but localization was not able to be determined 50, 51 . Other studies report cytosolic 52 or subapical localization 42 . One study has reported apical membrane localization in cultured choroid plexus epithelial cells 53 . A common feature of these outwardly directed efflux transporters is a broad substrate specificity and considerable overlap between transporters (see 54). PGP is unusual in that it intercepts lipid-soluble compounds (red symbols) as they pass through the internal leaflet of the plasma membrane and returns them to the extracellular fluid 55 , whereas BCRP and the MRPs bind their substrates from within the cell cytoplasm. Compounds can be exported from the cell by one or more of these efflux pathways. For example, a lipid-soluble compound that manages to avoid interception by PGP as it passes into the cell may then be metabolized by phase I enzymes (e.g. cytochrome P450 
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FACT CHECK 
Drug targeting to the central nervous system
This has been a major field of endeavor over the past 20-30 years. It has been largely unsuccessful in that few of the proposed methods appear to have been independently replicated, and we are not aware of any neuropharmaceutical drugs that have been identified using these methods. There are several comprehensive reviews of the methods that have been developed [58] [59] [60] . Here, we provide only a list of these methods (Table 1) , with some observations on their limitations. We deal in more detail with methods designed to allow entry of drugs into the brain by disruption of the blood-brain barrier. This is the only method of drug delivery that has translated to clinical practice, albeit on a limited basis. Newer, more focal methods hold promise of significant advances using this approach.
The following drug delivery approaches have been tried: (i) In vitro blood-brain or blood-CSF barrier models (see reviews in 61-64)
The hallmarks of success of such systems are generally held to be a high transendothelial resistance (TEER) and limited permeability to barrier integrity markers such as It is unclear whether these reflect the properties of vessels within the brain. The type of endothelial cells isolated in preparation of the cultures is often not clear 66 . But perhaps the biggest limitation of these systems is that few attempts have been made to characterize at the molecular level the barrier and transport properties in vitro compared to those in vivo. This would seem to be particularly important given the propensity for cells to transform in culture. Where attempts have been made, the extent to which the in vivo properties are retained is limited 67 .
(ii) Receptor-mediated and adsorptive-mediated transcytosis (see Table 1 )
Lajoie and Shusta 60 review a number of more recent developments using alternative targets on cerebral endothelial cells, but it is too soon to tell whether these will be more successful than earlier developed methods.
(iii) Influx transporters As indicated above, there are numerous influx transporters in brain endothelial cells. In the case of only a few, it has been possible to use these to achieve penetration of a therapeutic compound into the brain. The best known, and one of the earliest to be described, is L-DOPA for the treatment of Parkinson's disease, e.g. 68. Its introduction transformed the treatment of this condition, but, after prolonged experience, it is clear that it has serious clinical limitations.
(iv) Inhibition of efflux transporters (see above, 69, and Table 1) The number of ABC transporters that have been shown to be functionally effective at the blood-brain barrier is only a small proportion of the known total of 49. A huge number of drugs and other xenobiotics are excluded from the brain 70 , which explains the lack of specificity of ABC transporters. Unless some way could be found to limit the effect of the inhibitor to cerebral endothelial cells, and preferably only those in the neurological target area of the brain, this is unlikely to be a viable method of promoting drug entry to the brain.
(v) Modulation of integrity of the blood-brain barrier Three methods have been tried − osmotic opening, ultrasound, and electrical stimulation (Table 2) .
Reversible osmotic opening of the blood-brain barrier was first demonstrated in animals by Rapoport et al. 71 using a variety of hypertonic electrolyte and non-electrolyte solutions. Brightman et al. 72 showed that barrier opening to horseradish peroxidase was due to opening of cerebral vessel tight junctions. Since 1979, Neuwelt has pioneered the use of osmotic opening of the blood-brain barrier as a means of delivering chemotherapeutic agents to treat brain tumors 73 . He has built up an impressive array of animal and patient imaging techniques, which allowed careful evaluation of the use of hypertonic solutions to open the barrier under well-controlled, carefully monitored conditions and to develop methods for mitigating some of the potentially devastating side effects 74, 75 . Reversible osmotic opening of the blood-brain barrier is the only technique for improving drug delivery to the brain that has successfully translated to the clinic. It is not widely used, probably because it requires repeated hospital admissions and general anesthesia, as well as being associated with increased risk of stroke and epileptic seizures 76 and other surgical and neurological problems
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Focused ultrasound disruption of the blood-brain barrier in laboratory animals was first investigated in the 1950s 77 . In that study and in subsequent ones, it was necessary to perform a craniectomy in order to achieve sufficient ultrasound energy to produce effects in the brain (e.g. 78). A major advance was to combine intravenous injection of gas bubbles, previously developed as a contrast agent for ultrasound imaging, with focused ultrasound 79 ; this reduced the ultrasound power required to disrupt the blood-brain barrier and was shown to be effective through the intact skull in rabbits. Subsequent studies have evaluated the safety of the procedure 80 , effects of different anesthetic agents 80 , and feasibility in large animals 81 . The mechanism of the interaction between the micro-bubbles and the focused ultrasound beam is unclear. Several possibilities are discussed by Burgess and Hynynen 82 and by Timbie et al. 83 . The advantages of this approach compared to osmotic disruption of the blood-brain barrier are that (a) it is non-invasive (does not require craniotomy), (b) it can be targeted to a specific lesion, e.g. tumor, or region of neurological disorder such as the basal ganglia in Parkinson's disease, (c) it is transient, although the estimates of duration barrier opening have varied from 6 to 24 hours in different studies, and (d) under well-defined conditions of ultrasound parameters, there appears to be no evidence of ischemia, apoptosis, or cognitive dysfunction (tested in primates 82 ). Investigations so far have concentrated on the mechanical disruptive effects of the method, but studies are needed to investigate possible effects on cellular 
Modulation of integrity of the blood-brain barrier
See Table 2 Bypassing the barriers . Also, it needs to be considered whether the effects might be different in pathological brains.
What next?
The concentration in the past 25 years on developing in vitro systems for testing barrier permeability to drugs and the various drug delivery methods outlined above has been at the expense of fundamental research aimed at better understanding of brain barrier mechanisms. We list here some major questions, the answers to which might aid the development of more effective drug delivery strategies as well as our understanding of the involvement of brain barrier mechanisms in a wide range of neuropsychiatric conditions.
(i) Different approaches to drug development Given the overwhelming importance of efflux transporters in excluding drugs from the brain, we need better understanding of the molecular nature of their mechanism(s) of action, as this would allow the development of drugs that evade these mechanisms. However, there would still be a need to develop ways of targeting the drugs not just to the cerebral vasculature but also to specific brain regions. This might come from better knowledge of the molecular characteristics of cerebral endothelial and peripheral endothelial cells as well as identifying such differences in different brain regions, as suggested by Pachter's work 66, 85 .
(ii) Rapid high-throughput screening of drugs with potential for neurotherapeutic treatments
In the past, most such drugs have been developed in vitro but failed as useful agents in vivo because of inability to cross the bloodbrain barrier 86 . Two plausible approaches, on which a start has been made, are (a) to use in initial screens organisms that are easily available in large numbers, e.g. flies 87, 88 and zebrafish 89, 90 . These organisms utilize ABC efflux transporters as in mammals, although the morphological sites at which they function are different in invertebrates 87 and the actual ABC transporters that are functionally important may be different in different species. Also, (b) we require a better understanding of the ABC transporters in human brain barriers (adult and developing) and their level of function.
It should then be possible to devise appropriate cell-based screens using fluorophore-tagged drugs and competitors 91 .
(iii) What is the risk to the developing brain of drugs administered to pregnant women?
As indicated above, several ABC transporters are expressed at high levels in embryonic brain both in blood vessels and in the choroid plexuses 28, 35 . However, it is uncertain if expression levels can be equated to functional exclusion of drugs from the brain. If this can be shown, then coupled with similar transporter activity in the placenta, this suggests that the developing brain may be much better protected than is implied by the discredited but still current dogma that the blood-brain barrier in the embryo is unformed or "leaky" (see Text Box). Nevertheless, the loss of the placental protection in prematurely born infants may mean that they are more vulnerable to the ill effects of drugs than their full-term counterparts.
(iv) Involvement of barrier mechanism in brain disorders
The literature on possible involvement of blood-brain barrier mechanisms is too extensive to cover in this review. Recent papers describing different aspects of the pathobiology of brain barrier mechanisms are 92, which is particularly comprehensive, and 69,93-95. For decades, the focus has been on dysfunction defined by supposed disruption of the blood-brain barrier often defined with unsuitable markers (see Text Box). Only comparatively recently has attention turned to the possibility that transporter dysfunction may be involved. It is usually unclear whether barrier dysfunction is a cause or a consequence of a particular neurological disorder. This is an area in which further research with modern technology is likely to be fruitful.
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